European Commission has approved Braftovi in combination with Mektovi for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union member states, as well as Liechtenstein, Iceland and Norway.
Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.
